CareDx, Inc. CDNA

CareDx, Inc. es una empresa de soluciones de medicina de precisión. La empresa se enfoca en el descubrimiento, desarrollo y comercialización de soluciones diagnósticas clínicamente diferenciadas para pacientes y cuidadores de trasplantes. La empresa ofrece servicios de pruebas, productos y soluciones digitales para el viaje del paciente antes y después del trasplante, y es un proveedor de información basada en genómica para pacientes trasplantados. Sus servicios de pruebas comercialmente disponibles consisten en AlloSure Kidney, una solución de ADN libre de células derivadas del donante (dd-cfDNA) para pacientes trasplantados de riñón; AlloMap Heart, una solución de expresión génica para pacientes trasplantados de corazón; AlloSure Heart, una solución de dd-cfDNA para pacientes trasplantados de corazón, y AlloSure Lung, una solución de dd-cfDNA para pacientes trasplantados de pulmón. El portafolio de productos de la empresa incluye AlloSeq Tx, QTYPE, Olerup SSP, AlloSeq HCT y AlloSeq cfDNA. Desarrolla y ofrece servicios de pruebas de vigilancia diagnóstica para diversos receptores de trasplantes.

• GlobeNewswire Inc. 5 oct

  Immunogenomics Market Size, Share, Trends, and Growth Forecast, 2026-2033 | NGS and Personalized Medicine Drive Market Toward USD 9.82 Billion at 5.97% CAGR

  The global immunogenomics market is projected to grow from USD 6.32 billion in 2025 to USD 9.82 billion by 2033, expanding at a CAGR of 5.97%. Growth is driven by advancements in next-generation sequencing technologies, increasing demand for personalized medicine, and rising prevalence of immune-related disorders. Key applications include oncology, infectious disease research, vaccine development, and autoimmune disorder studies, with adoption across hospitals, diagnostic laboratories, pharmaceutical companies, and academic institutions.

  

• Zacks Investment Research 30 sept

  Consumer Confidence Falls Amid Ongoing Geopolitical Tensions: 4 Picks

  Consumer confidence fell 6.7% to 81.9 in September 2026, hitting its lowest level since April 2014, driven by concerns about labor market conditions and Middle East geopolitical tensions. The Federal Reserve hiked interest rates by 25 basis points and hinted at further increases. In response, four defensive stocks from healthcare and consumer staples sectors are recommended: Bausch Health Companies, CareDx, Dole, and The Chefs' Warehouse.

  

• Zacks Investment Research 14 sept

  4 Healthcare Stocks to Play Safe as Fed Gears Up for Rate Hike

  With inflation remaining stubbornly high at 3.4% annually and a 90% probability of a Federal Reserve rate hike expected, the article recommends four defensive healthcare stocks: Amgen, Bausch Health, CareDx, and Centene. CareDx and Centene are expected to deliver over 100% earnings growth this year, while all four stocks have seen improved earnings estimates over the past 60 days.

  

• Zacks Investment Research 9 sept

  Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks

  Rising oil prices amid escalating Middle East tensions between the US and Iran are driving market volatility and inflation concerns. The Federal Reserve is expected to hike interest rates next month. Investors are rotating toward defensive stocks in consumer staples and healthcare sectors.

  

• The Motley Fool 31 jul

  Why CareDx Stock Jumped Today

  CareDx stock surged 14.72% after the precision medicine diagnostics company raised its full-year revenue and earnings forecasts. The company reported adjusted net income more than tripled to $20 million ($0.37 per share), significantly exceeding Wall Street estimates of $0.23 per share. Growth was driven by increased demand for non-invasive transplant monitoring tests, favorable reimbursement dynamics, and CMS coverage affirmation for kidney, heart, and lung transplant surveillance testing.